TTNP logo

TITAN PHARMACEUTICAL INC

TTNP

TTNP: Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

more

Show TTNP Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of TTNP by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by TTNP's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jun 03, 2021 Issue: Health Issues
  • $10,000 Apr 20, 2021 Issue: None
  • $10,000 Jan 12, 2021 Issue: Health Issues
  • $20,000 Oct 19, 2020 Issue: Health Issues
  • $10,000 Oct 07, 2020 Issue: Health Issues
  • $20,000 Jul 13, 2020 Issue: Health Issues
  • $10,000 Jul 08, 2020 Issue: Health Issues
  • $10,000 Apr 20, 2020 Issue: Health Issues
  • $20,000 Apr 16, 2020 Issue: Health Issues
  • $20,000 Jan 17, 2020 Issue: Health Issues
  • $20,000 Oct 17, 2019 Issue: Health Issues
  • $20,000 Jul 19, 2019 Issue: Health Issues
  • $20,000 Apr 17, 2019 Issue: Health Issues
  • $10,000 Apr 14, 2019 Issue: Alcohol and Drug Abuse Health Issues
  • $10,000 Feb 22, 2019 Issue: None
  • $10,000 Jan 16, 2019 Issue: Health Issues
U.S. Patents

New patents grants

  • Patent Title: Heterogeneous implantable devices for drug delivery Nov. 13, 2018
  • Patent Title: Heterogeneous implantable devices for drug delivery Oct. 30, 2018
  • Patent Title: Implantable polymeric device for sustained release of dopamine agonist Mar. 08, 2016
  • Patent Title: Implantable polymeric device for sustained release of dopamine agonist Oct. 07, 2014
  • Patent Title: Implantable polymeric device for sustained release of buprenorphine Jun. 15, 2010
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of TTNP in WallStreetBets Daily Discussion

TTNP News

Recent insights relating to TTNP

CNBC Recommendations

Recent picks made for TTNP stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TTNP

Corporate Flights

Flights by private jets registered to TTNP